A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Public ClinicalTrials.gov record NCT03694522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1
Study identification
- NCT ID
- NCT03694522
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Five Prime Therapeutics, Inc.
- Industry
- Enrollment
- 155 participants
Conditions and interventions
Conditions
Interventions
- Bemarituzumab Biological
- Modified FOLFOX6 Drug
- Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 13, 2018
- Primary completion
- Sep 22, 2020
- Completion
- May 12, 2022
- Last update posted
- Feb 27, 2024
2018 – 2022
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| The Oncology Institute of Tuscon | Tucson | Arizona | 85745 | — |
| Marin Cancer Care, Inc-California Cancer Care A Medical Group, Inc | Greenbrae | California | 94904 | — |
| Sutter Medical Group | Sacramento | California | 95816 | — |
| UCLA Medical Centre - Santa Monica Hematology and Oncology | Santa Monica | California | 90404 | — |
| Innovative Clinical Research Institute (ICRI) | Whittier | California | 90603 | — |
| Yale Cancer Center | New Haven | Connecticut | 06519 | — |
| Hartford Healthcare Cancer Institute at The Hospital of Central Connecticut | Plainville | Connecticut | 06062 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Northwestern Medicine Cancer Center Warrenville | Warrenville | Illinois | 60555 | — |
| University of Kansas Medical Center | Westwood | Kansas | 66205 | — |
| Oschsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Josephine Ford Cancer Center-Henry Ford Cancer Center | Detroit | Michigan | 48202 | — |
| Summit Medical Group. Morristown Oncology | Morristown | New Jersey | 07960 | — |
| University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) | Rochester | New York | 14642 | — |
| Stony Brook Cancer Center | Stony Brook | New York | 11794 | — |
| Westchester Institute For Treatment Of Cancer & Blood Disorders | White Plains | New York | 10601 | — |
| UNC- Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| FirstHealth Outpatient Cancer Center | Pinehurst | North Carolina | 28374 | — |
| St. Luke's Physician Group - St. Luke's Cancer Care Associates | Bethlehem | Pennsylvania | 18015 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29435 | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37909 | — |
| Arlington Cancer Center | Arlington | Texas | 76012 | — |
| Utah Cancer Specialists (Intermountain Hematology - Oncology Associates) UCS Cancer Center | South Salt Lake | Utah | 84106 | — |
| Virginia Mason Seattle Main Clinic | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 160 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03694522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2024 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03694522 live on ClinicalTrials.gov.